Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

Shares of Vertex Pharmaceuticals gained about 6% Friday morning, after the pharmaceutical company won U.S. approval for the ...

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...

This was the stock's fourth consecutive day of gains.